Vijaya Diagnostic Centre
VIJAYA · NSE · Healthcare · India
Financials at a glance
Source: Yahoo FinanceAnnual
Quarterly · last 5
Revenue (FY2026)
₹814 Cr
Net margin
21.2%
Revenue CAGR (3y)
+21.0%
Profit CAGR (3y)
+26.9%
Net profit (FY2026)
₹173 Cr
Ask MarketChacha about VIJAYA
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Financials
Yearly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| FY2026 | ₹814 Cr | ₹173 Cr | 21.2% |
| FY2025 | ₹681 Cr | ₹143 Cr | 21.0% |
| FY2024 | ₹548 Cr | ₹119 Cr | 21.7% |
| FY2023 | ₹459 Cr | ₹85 Cr | 18.4% |
Quarterly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| Q1 FY27 | ₹231 Cr | ₹53 Cr | 23.0% |
| Q4 FY26 | ₹219 Cr | ₹48 Cr | 21.8% |
| Q3 FY26 | ₹205 Cr | ₹43 Cr | 21.0% |
| Q2 FY26 | ₹202 Cr | ₹43 Cr | 21.5% |
| Q1 FY26 | ₹188 Cr | ₹38 Cr | 20.4% |
Figures as reported, in ₹ (crore). Source: Yahoo Finance.
Filings & announcements
2026
100% acquisition of integrated diagnostic business undertaking of Arya Wellness Centre, Guwahati, Assam.
BSE9/11/2026Execution of Business Transfer Agreement ("BTA") for 100% acquisition of integrated diagnostic business undertaking of Arya Wellness Centre, Guwahati, Assam on slump sale.
BSE9/11/2026Board Meeting Outcome for Outcome Of The Board Meeting - Acquisition
Outcome of Board Meeting under Regulation 30 of SEBI (LODR) Regulations, 2015 - Approval for Execution of Business Transfer Agreement (BTA) for 100% acquisition of the integrated diagnostic ....
BSE9/11/2026Resignation of Company secretary
BSE8/26/2026Cessation of Dr. Manjula Anagani as Independent Director due to completion of tenure w.e.f closing of business hours on 21.08.2026
BSE8/21/2026Cessation of Dr. Manjula Anagani as Independent Director on completion of tenure w.e.f 21.08.2026
BSE8/21/2026Information relating to 24th Annual general meeting, cut-off date for remote e-voting and e-voting at AGM
BSE8/19/2026materialPress Release on Q1 Un-audited financial results for FY 27
BSE8/6/2026Investor Presentation on Un-audited results for the Quarter ended June 30, 2026
BSE8/6/2026Press Release on Un-audited financial results for the quarter ended June 30, 2026
BSE8/6/2026Un-Audited Financial Results For The Quarter Ended June 30, 2026
Un-audited financial results for the quarter ended June 30, 2026 on consolidated & Standalone basis
BSE8/6/2026The Board of Directors in their meeting held on August 6, 2026 have approved the financial results for the quarter ended June 30, 2026
BSE8/6/2026Vijaya Diagnostic Centre Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Un-audit financial ....
BSE7/28/2026material
In the news
- Beyond hospitals: 2 virtually debt-free healthcare stocks with 35%+ profit growthThe Financial Express · 10/17/2026
- Diagnostic Stocks 2026: Dr Lal PathLabs, Vijaya DiagnosticUnivest · 10/16/2026
- Is India’s diagnostics sector poised for a long-term growth upswing? Axis Securities sees opportunity in three stocksLivemint · 10/12/2026
- Axis Direct bullish on Dr Lal PathLabs, Vijaya Diagnostic and Nephrocare, assigns 'Buy' ratings with up to...Moneycontrol.com · 10/12/2026
- Vijaya Diagnostic Centre (VIJAYA.NS) Slips 1.23% to ₹1482.9 — Support at ₹1408.76 in Focus - Short Term Trading Ideassiam.in · 9/29/2026
- Vijaya Diagnostic Centre vs Krsnaa Diagnostics vs Suraksha DiagnoUnivest · 9/25/2026
- Vijaya Diagnostic Centre shareholders adopt FY26 results at 24th AGMscanx.trade · 9/24/2026
- Trade Spotlight: How should you trade Vijaya Diagnostic Centre, IDFC First Bank, Radico Khaitan, MCX...Moneycontrol.com · 9/24/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.